61542-10-7

Basic information

• Product Name: 1-Iodo-3-methoxypropane
• Synonyms: 1-Iodo-3-methoxypropane;3-Methoxypropyl iodide
• CAS NO: 61542-10-7
• Molecular Formula: C₄H₉IO
• Molecular Weight: 200.014
• Mol File: 61542-10-7.mol
• Article Data: 9

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-Iodo-3-methoxypropane(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Iodo-3-methoxypropane(61542-10-7)
• EPA Substance Registry System: 1-Iodo-3-methoxypropane(61542-10-7)

Safety Data

• Hazardous Substances Data: 61542-10-7(Hazardous Substances Data)

Usage

Appearance

Colorless liquid

Use

Reagent in organic synthesis

Reactivity

Highly reactive alkylating agent

Applications

Synthesis of pharmaceuticals and complex organic molecules

Safety

Handle with caution and proper safety measures

Upstream product

• 36215-07-3 1-Chloro-3-methoxypropane 
• 1589-49-7 methoxypropanol 
• 36865-41-5 3-bromopropanol methyl ether 
• 54646-36-5 3-methoxypropyl p-toluenesulfonate 

Downstream Products

• 66897-58-3 N-(2-Chloro-benzoyl)-N-(3-methoxy-propyl)-benzenesulfonamide 
• 895240-78-5 4-bromo-3-(3-methoxy-propoxy)-benzoic acid methyl ester 
• 51112-70-0 2-(3-methoxypropyl)cyclohexan-1-one 
• 59117-58-7 3-(4-methoxyphenyl)propyl methyl ether 
• 2046-33-5 3-methoxypropylbenzene 
• 1020734-59-1 1-fluoro-3-[(3-methoxypropyl)sulfonyl]benzene 
• 1187941-43-0 C₃₃H₅₇N₃O₉S 
• 895240-72-9 3-(3-methoxy-propoxy)-4-methyl-benzoic acid methyl ester 
• 865156-55-4 4-bromo-2-(3-methoxypropoxy)pyridine 
• 605660-77-3 5-(4-aminophenyl)-6-(2-methoxyethyl)thieno[2,3-d]pyrimidin-4-amine 
• 172901-02-9 (1S,2S,4R,2'S)-(4-butylcarbamoyl-2-hydroxy-1-{2'-[4-methoxy-3-(3-methoxy-propoxy)-benzyl]-3'-methyl-butyl}-pentyl)-carbamic acid tert-butyl ester 
• 866584-85-2 4-methoxy-1-(4-nitrophenyl)butan-1-one 
• 5084-33-3 6-methoxyhex-1-ene 

Relevant articles and documents

Regio- And Stereoselective Synthesis of Multi-Alkylated Allylic Boronates through Three-Component Coupling Reactions between Allenes, Alkyl Halides, and a Diboron Reagent

Multisubstituted allylic boronates are attractive and valuable precursors for the rapid and stereoselective construction of densely substituted carbon skeletons. Herein, we report the first synthetic approach for differentially 2,3,3-trialkyl-substituted allylic boronates that contain a stereodefined tetrasubstituted alkene structure. Copper(I)-catalyzed regio- and stereoselective three-component coupling reactions between gem-dialkylallenes, alkyl halides, and a diboron reagent afforded sterically congested allylic boronates. The allylboration of aldehydes diastereoselectively furnished the corresponding homoallylic alcohols that bear a quaternary carbon. A computational study revealed that the selectivity-determining mechanism was correlated to the coordination of a boryl copper(I) species to the allene substrate as well as the borylcupration step.

ALKOXY BIS-HETEROARYL DERIVATIVES AS MODULATORS OF PROTEIN AGGREGATION

The present invention relates to certain bis-heteroaryl compounds, pharmaceutical compositions containing them, and methods of using them, including methods for preventing, reversing, slowing, or inhibiting protein aggregation, and methods of treating diseases that are associated with protein aggregation, including neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, Lewy body disease, Parkinson's disease with dementia, fronto-temporal dementia, Huntington's Disease, amyotrophic lateral sclerosis, and multiple system atrophy, and cancer including melanoma.

IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS

The present invention relates to novel imidazo[1,2-b]pyridazine derivatives which are inhibitors of the phosphodiesterase 10 enzyme (PDE10) and which are useful for the treatment or prevention of neurological, psychiatric and metabolic disorders in which the PDE10 enzyme is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, to the use of such compounds or pharmaceutical compositions for the prevention or treatment of neurological, psychiatric and metabolic disorders and diseases.